By: IPP Bureau
Last updated : May 13, 2026 4:33 pm
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Vyome Holdings, Inc. has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, securing an exclusive license to develop and commercialize a selective JAK1/3 inhibitor and a selective JAK1 inhibitor for immune-inflammatory diseases.
Janus kinase (JAK) inhibitors are immunomodulatory therapies used to treat autoimmune and inflammatory disorders by blocking JAK enzymes.
According to industry estimates, the global JAK inhibitors market is projected to grow from $23.56 billion in 2025 to $56.78 billion by 2030, reflecting strong demand for safer and more targeted immunology treatments.
“We are delighted that Impetis trusted the Vyome team to lead the development of such valuable assets,” said Dr. Shiladitya Sengupta, Co-Founder of Vyome and Associate Professor of Medicine at Harvard Medical School. “We believe that selective JAK inhibitors are the future in immunology, and that Impetis has provided compelling preclinical data to show clear differentiation from early-generation JAK inhibitors.”
He added that while Vyome remains focused on advancing VT-1953 for malignant fungating wounds in cancer patients, the new JAK inhibitor programs broaden the company’s pipeline into large immune-inflammatory therapeutic areas.
“We are building Vyome with focus and discipline in one of the most attractive segments in biotech, the immuno-inflammatory market, expected to exceed $430 billion by 2034,” said Venkat Nelabhotla, CEO of Vyome. “This transaction highlights the strength of the US–India innovation corridor in sourcing high-quality assets efficiently.”
Nelabhotla noted that the deal structure is designed to remain capital efficient, with future consideration linked to commercialization milestones and future development expected to be pursued through non-dilutive pathways.
“We are pleased to partner with Vyome on the development of our JAK inhibitor programs,” said KRS Jamwal, Chairman of Impetis. “This partnership reflects Impetis’ ongoing commitment to translating its deep preclinical portfolio into clinical value.”